Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102687 · ClinicalTrials.gov registry record · Phase 2
Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT00102687 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 151 participants.
The verdict
NCT00102687, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if azacitidine, combined with Best Supportive Care (BSC), is effective in treating myelodysplastic syndromes (MDS) when given according to a different doses and dosing schedules.
Interventions
- DRUG azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2005-01-01 |
| Est. Completion | 2008-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102687
The ClinicalTrials.gov registry entry for NCT00102687 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which azacitidine is the first listed.
NCT00102687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00102687 about?
NCT00102687 is a clinical study titled "Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes". The purpose of this study is to determine if azacitidine, combined with Best Supportive Care (BSC), is effective in treating myelodysplastic syndromes (MDS) when given according to a different doses and dosing schedules.
What is the current status of trial NCT00102687?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2005-01-01. Estimated completion is 2008-08-01.
What interventions are being tested in trial NCT00102687?
The interventions under investigation include: azacitidine (DRUG).
Who is sponsoring clinical trial NCT00102687?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.